The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Borodkina D.A.

GBOU VPO "Kemerovskaia gosudarstvennaia meditsinskaia akademiia"

Gruzdeva O.V.

Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia;
Kemerovo State Medical Academy, Kemerovo, Russia

Kvitkova L.V.

Kemerovskaia oblastnaia klinicheskaia bol'nitsa

Barbarash O.L.

Kemerovskaia oblastnaia klinicheskaia bol'nitsa

Is visceral obesity the cause of obesity paradox?

Authors:

Borodkina D.A., Gruzdeva O.V., Kvitkova L.V., Barbarash O.L.

More about the authors

Journal: Problems of Endocrinology. 2016;62(6): 33‑39

DOI: 10.14341/probl201662633-39

Views: 3425

Downloaded: 56

Download PDF (RU)
Contact the author
Table of contents

IS VISCERAL OBESITY THE CAUSE OF OBESITY PARADOX?
IS VISCERAL OBESITY THE CAUSE OF OBESITY PARADOX?

To cite this article:

Borodkina DA, Gruzdeva OV, Kvitkova LV, Barbarash OL. Is visceral obesity the cause of obesity paradox? Problems of Endocrinology. 2016;62(6):33‑39. (In Russ.)
https://doi.org/10.14341/probl201662633-39

МСФ на ЯМ
Close metadata

Obesity is one of the 10 risk factors of death. Many epidemiological studies have shown that overweight and obesity are associated with 44% cases of diabetes type 2, and 23% of cases of coronary heart disease. The body mass index (BMI) is traditionally a diagnostic marker of obesity and overweight are considered. However, in the last 15 years, there has been work on the «paradox» of obesity. So the obese long-term prognosis and stroke are more favorable than individuals without excess weight and obesity. A deeper analysis of the data showed that the highest risk of developing cardiovascular disease and disorders of carbohydrate metabolism associated with visceral obesity. This is largely due to metabolic disorders occurring on the background of visceral obesity, such as insulin resistance, hyperglycemia, dyslipidemia, an imbalance of adipokines and markers of inflammation. These changes in individuals with visceral obesity can occur regardless of the value of BMI.

Keywords:

visceral obesity
insulinoresistance
cardiovascular disease
adipokines

Authors:

Borodkina D.A.

GBOU VPO "Kemerovskaia gosudarstvennaia meditsinskaia akademiia"

Gruzdeva O.V.

Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia;
Kemerovo State Medical Academy, Kemerovo, Russia

Kvitkova L.V.

Kemerovskaia oblastnaia klinicheskaia bol'nitsa

Barbarash O.L.

Kemerovskaia oblastnaia klinicheskaia bol'nitsa

List of references:

  1. Krysanova VS, Zhuravleva MV, Serebrova SY. Sotsial'naya i ekonomicheskaya znachimost' izbytochnoi massy tela i ozhireniya v Rossiiskoi Federatsii. Osnovnye podkhody k lecheniyu ozhireniya. Russkii meditsinskii zhurnal. 2015;23(26):1534-1537. (In Russ.).
  2. Ogden CL, Carroll MD, Lawman HG, et al. Trends in Obesity Prevalence Among Children and Adolescents in the United States, 1988—1994 Through 2013—2014. JAMA. 2016;315(21):2292-2299. doi: 10.1001/jama.2016.6361
  3. Gallus S, Lugo A, Murisic B, et al. Overweight and obesity in 16 European countries. Eur J Nutr. 2014;54(5):679-689. doi: 10.1007/s00394-014-0746-4
  4. Flegal KM. Prevalence and Trends in Obesity Among US Adults, 1999—2008. JAMA. 2010;303(3):235. doi: 10.1001/jama.2009.2014
  5. WHO. The top 10 causes of death. Fact sheet N°310. Updated May 2014. Available from: http://www.who.int/mediacentre/factsheets/fs310/ru
  6. Barbarash OL, Karetnikova VN, Kashtalap VV. Patient after myocardial infarction: how to reduce the risk of recurrent ischemic events? Cardiosomaticа. 2015;(2):12-19. (In Russ.).
  7. Skinner AC, Perrin EM, Moss LA, Skelton JA. Cardiometabolic Risks and Severity of Obesity in Children and Young Adults. N Engl J Med. 2015;373(14):1307-1317. doi: 10.1056/NEJMoa1502821
  8. Wong E, Tanamas SK, Wolfe R, et al. The role of obesity duration on the association between obesity and risk of physical disability. Obesity. 2015;23(2):443-447. doi: 10.1002/oby.20936
  9. World Health Organization Media Centre. Obesity and overweight. Fact sheet no 311. Geneva: World Health Organization; 2013
  10. Kulikov VA. Fremingemskoe issledovanie serdtsa: 65 let izucheniya prichin atero-skleroza. Vestnik Vitebskogo gosudarstvennogo meditsinskogo universiteta. 2012;11(2):16-23. (In Russ.).
  11. Butrova SA, Dzgoeva FK. Vistseral'noe ozhirenie — klyuchevoe zveno metabolicheskogo sindroma. Obesity and metabolism. 2004;(1);10-13. (In Russ.). doi: 10.14341/2071-8713-5173
  12. Ametov AS, Demidova TY, Tselikovskaya AL Ozhirenie i serdechnososudistye zabolevaniya. Terapevticheskii arkhiv. 2001;(8):69-72. (In Russ.).
  13. WHO. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series 854. Geneva: World Health Organization. 1995.
  14. Lavie CJ, De Schutter A, Milani RV. Body composition and the obesity paradox in coronary heart disease: can heavier really be healthier? Heart. 2015;101(20):1610-1611. doi: 10.1136/heartjnl-2015-307966
  15. Bucholz EM, Beckman AL, Krumholz HA, Krumholz HM. Excess weight and life expectancy after acute myocardial infarction: The obesity paradox reexamined. Am Heart J. 2016;172:173-181. doi: 10.1016/j.ahj.2015.10.024
  16. Karrowni W, Kennedy K, Jones P, et al. Obesity Paradox among Survivors of Acute Myocardial Infarction and Its Interaction with Time. J Am Coll Cardiol. 2015;65(10):A31. doi: 10.1016/s0735-1097(15)60031-6
  17. Aparicio HJ, Himali J, Beiser A, et al. Body Weight and Survival after Stroke: Exploring the «Obesity Paradox» in the Framingham Study (I12-2A). Neurology. 2015;84(14Suppl 1):I12-2A.
  18. Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: A systematic review and metaanalysis. Ann Intern Med. 2013;159(11):758-769. doi: 10.7326/0003-4819-159-11-201312030-00008
  19. Brisbois TD, Farmer AP, McCargar LJ. Early markers of adult obesity: a review. Obes Rev. 2012;13(4):347-367. doi: 10.1111/j.1467-789X.2011.00965.x
  20. Lopes HF, Corrêa-Giannella ML, Consolim-Colombo FM, Egan BM. Visceral adiposity syndrome. Diabetol Metab Syndr. 2016;8(1). doi: 10.1186/s13098-016-0156-2
  21. Vague J. La differénciation sexuelle, facteur determinant des formes de l’obésité. Presse Med. 1947;30:339-340.
  22. Okosun IS, Seale JP, Lyn R. Commingling effect of gynoid and android fat patterns on cardiometabolic dysregulation in normal weight American adults. Nutrition & Diabetes. 2015;5(5):e155. doi: 10.1038/nutd.2015.5
  23. Kuznetsova AV, Teplyakov AT. Otsenka roli insulinorezistentnosti u bol'nykh sakhar-nym diabetom posle endovaskulyarnykh vmeshatel'stv. Mezhdunarodnyi zhurnal prikladnykh i fundamental'nykh issledovanii. 2011;(9):97. (In Russ.).
  24. Usov VYu. Conventional X-ray to Diagnostic Radiology. Medical Visualization. 2008;1:138. (In Russ.).
  25. Zavadovsky KV, Lishmanov YB. Summary report: scientific-practical seminar modern methods of radiation diagnosis of coronary heart disease. Sibirskii meditsinskii zhurnal. 2015;30(4):75-75. (In Russ.).
  26. Okorokov PL, Vasyukova OV, Vorontsov AV. The methods for the characteristic of adipose tissue in the organism and their clinical significance. Problems of Endocrinology. 2014;60(3):53-58. (In Russ.). doi: 10.14341/probl201460353-58
  27. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism. 1987;36(1):54-59. doi: 10.1016/0026-0495(87)90063-1
  28. Sjostrom L, Kvist H, Cederblad A, Tylen U. Determination of total adipose tissue and body fat in women by computed tomography, 40K, and tritium. Am J Physiol. 1986;250(6 Pt 1):E736-E745.
  29. Veilleux A, Cote JA, Blouin K, et al. Glucocorticoid-induced androgen inactivation by aldo-keto reductase 1C2 promotes adipogenesis in human preadipocytes. AJP: Endocrinology and Metabolism. 2012;302(8):E941-E949. doi: 10.1152/ajpendo.00069.2011
  30. Bjorntorp P. Metabolic Implications of Body Fat Distribution. Diabetes Care. 1991;14(12):1132-1143. doi: 10.2337/diacare.14.12.1132
  31. Petrus P, Rosqvist F, Edholm D, et al. Saturated fatty acids in human visceral adipose tissue are associated with increased 11-β-hydroxysteroid-dehydrogenase type 1 expression. Lipids Health Dis. 2015;14(1). doi: 10.1186/s12944-015-0042-1
  32. Tchernof A, Despres JP. Pathophysiology of Human Visceral Obesity: An Update. Physiol Rev. 2013;93(1):359-404. doi: 10.1152/physrev.00033.2011
  33. Masuzaki H, Flier JS. Tissue-specific glucocorticoid reactivating enzyme, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1)—a promising drug target for the treatment of metabolic syndrome.Curr Drug Targets Immune Endocr Metabol Disord.2003;3(4):255-262. doi: 10.2174/1568008033340135
  34. Britton KA, Fox CS. Ectopic Fat Depots and Cardiovascular Disease. Circulation. 2011;124(24):e837-e841. doi: 10.1161/circulationaha.111.077602
  35. Mahabadi AA, Massaro JM, Rosito GA, et al. Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J. 2008;30(7):850-856. doi: 10.1093/eurheartj/ehn573
  36. Lima MMO, Pareja JC, Alegre SM, et al. Visceral fat resection in humans: Effect on insulin sensitivity, beta-cell function, adipokines, and inflammatory markers. Obesity. 2013;21(3):E182-E189. doi: 10.1002/oby.20030
  37. Bergman RN, Kim SP, Catalano KJ, et al. Why Visceral Fat is Bad: Mechanisms of the Metabolic Syndrome. Obesity. 2006;14(2S):16S-19S. doi: 10.1038/oby.2006.277
  38. Jensen MD. Is Visceral Fat Involved in the Pathogenesis of the Metabolic Syndrome? Human Model. Obesity. 2006;14(2S):20S-24S. doi: 10.1038/oby.2006.278
  39. Hall JE, da Silva AA, do Carmo JM, et al. Obesity-induced Hypertension: Role of Sympathetic Nervous System, Leptin, and Melanocortins. J Biol Chem. 2010;285(23):17271-17276. doi: 10.1074/jbc.R110.113175
  40. Odegaard JI, Chawla A. Pleiotropic Actions of Insulin Resistance and Inflammation in Metabolic Homeostasis. Science. 2013;339(6116):172-177. doi: 10.1126/science.1230721
  41. Hardy OT, Czech MP, Corvera S. What causes the insulin resistance underlying obesity? Current Opinion in Endocrinology & Diabetes and Obesity. 2012;19(2):81-87. doi: 10.1097/MED.0b013e3283514e13
  42. Kim JI, Huh JY, Sohn JH, et al. Lipid-Overloaded Enlarged Adipocytes Provoke Insulin Resistance Independent of Inflammation. Mol Cell Biol. 2015;35(10):1686-1699. doi: 10.1128/mcb.01321-14
  43. Kovalik JP, Slentz D, Stevens RD, et al. Metabolic Remodeling of Human Skeletal Myocytes by Cocultured Adipocytes Depends on the Lipolytic State of the System. Diabetes. 2011;60(7):1882-1893. doi: 10.2337/db10-0427
  44. Bornfeldt Karin E, Tabas I. Insulin Resistance, Hyperglycemia, and Atherosclerosis. Cell Metabolism. 2011;14(5):575-585. doi: 10.1016/j.cmet.2011.07.015
  45. Matsuda M, Shimomura I. Increased oxidative stress in obesity: Implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer. Obes Res Clin Pract. 2013;7(5):e330-e341. doi: 10.1016/j.orcp.2013.05.004
  46. Litvinova LS, Vasilenko MA, Zatolokin PA, et al. Adipokines in metabolic processes regulating during obesity treatment. Diabetes mellitus. 2014;17(3):51-59. (In Russ.). doi: 10.14341/DM2014351-5947.
  47. Könner AC, Brüning JC. Selective Insulin and Leptin Resistance in Metabolic Disorders. Cell Metabolism. 2012;16(2):144-152. doi: 10.1016/j.cmet.2012.07.004
  48. Ott AV, Chumakova GA, Veselovskaya NG. Znachenie leptinorezistentnosti v razvitii razlichnykh metabolicheskikh fenotipov ozhireniya. Rossiiskii kardiologicheskii zhurnal. 2016;(4):4-18. (In Russ.). doi: 10.15829/1560-4071-2016-4-14-18
  49. Grundy SM. Metabolic syndrome update. Trends Cardiovasc Med. 2016;26(4):364-373. doi: 10.1016/j.tcm.2015.10.004
  50. Yokota T, Meka CSR, Medina KL, et al. Paracrine regulation of fat cell formation in bone marrow cultures via adiponectin and prostaglandins. J Clin Invest. 2002;109(10):1303-1310. doi: 10.1172/jci0214506
  51. Hardy OT, Perugini RA, Nicoloro SM, et al. Body mass index-independent inflammation in omental adipose tissue associated with insulin resistance in morbid obesity. Surg Obes Relat Dis. 2011;7(1):60-67. doi: 10.1016/j.soard.2010.05.013
  52. Hui X, Feng T, Liu Q, et al. The FGF21-adiponectin axis in controlling energy and vascular homeostasis. J Mol Cell Biol. 2016;8(2):110-119. doi: 10.1093/jmcb/mjw013
  53. Kvitkova LV, Borodkina DA, Gruzdeva OV, Barbarash OL, Silonova AA, Terletskaia OS. The levels of leptin, adiponectin, and free fatty acids in the patients of different body weight presenting with myocardial infarction and elevated ST segment. Problems of Endocrinology. 2013;59(3):8-12. (In Russ.). doi: 10.14341/probl20135938-12
  54. Alexopoulos N, Katritsis D, Raggi P. Visceral adipose tissue as a source of inflammation and promoter of atherosclerosis. Atherosclerosis. 2014;233(1):104-112. doi: 10.1016/j.atherosclerosis.2013.12.023
  55. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85-97. doi: 10.1038/nri2921
  56. Michaud M, Balardy L, Moulis G, et al. Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc. 2013;14(12):877-882. doi: 10.1016/j.jamda.2013.05.009
  57. Esser N, Legrand-Poels S, Piette J, et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(2):141-150. doi: 10.1016/j.diabres.2014.04.006
  58. Fuentes E, Fuentes F, Vilahur G, et al. Mechanisms of Chronic State of Inflammation as Mediators That Link Obese Adipose Tissue and Metabolic Syndrome. Mediators Inflamm. 2013;2013:1-11. doi: 10.1155/2013/136584

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.